Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 01
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Neurocrine Biosciences Inc
NBIX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$141.84
3.49
2.52%
Últ. Act.: Oct 1, 4:08 AM
$141.70
3.35
2.42%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Neurocrine Biosciences Financials
Neurocrine Biosciences (NBIX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the analyst consensus estimate of $1.34 by 112.69 percent. This is a 72.73 percent increase over earnings of $1.65 per share
Benzinga Newsdesk
PRO
Neurocrine Biosciences Q1 Adj. EPS $1.94 Beats $1.61 Estimate, Sales $814.500M Beat $763.112M Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.94 per share which beat the analyst consensus estimate of $1.61 by 20.5 percent. This is a 177.14 percent increase over earnings of $0.70 per share
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance
Neurocrine shares fell 8% after mixed earnings, strong Ingrezza sales, and a 2026 outlook that met expectations. Analysts see long-term upside despite short-term pressure.
Vandana Singh
Neurocrine Biosciences Q4 Earnings Assessment
Benzinga Insights
PRO
Neurocrine Biosciences Expects FY26 INGREZZA Net Product Sales Of $2.70B-$2.80B
Full-Year 2026 Financial Guidance Range(in millions)Low HighINGREZZA Net Product Sales 1$ 2,700 $
Benzinga Newsdesk
